Robert Gut Sells 25,613 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 25,613 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares of the company’s stock, valued at $796,260.04. This trade represents a 44.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robert Gut also recently made the following trade(s):

• On Thursday, November 6th, Robert Gut sold 31,434 shares of uniQure stock. The shares were sold at an average price of $27.26, for a total transaction of $856,890.84.

uniQure Stock Down 1.6%

QURE stock opened at $22.00 on Friday. The company has a 50 day moving average of $24.87 and a two-hundred day moving average of $27.65. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -5.01 and a beta of 0.68. uniQure N.V. has a 12-month low of $7.76 and a 12-month high of $71.50. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The company had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. On average, equities analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. Private Trust Co. NA acquired a new stake in shares of uniQure in the third quarter worth $28,000. Jones Financial Companies Lllp lifted its position in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure in the third quarter valued at about $50,000. FNY Investment Advisers LLC increased its stake in shares of uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 718 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in shares of uniQure by 358.0% in the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on QURE. UBS Group set a $95.00 price target on uniQure in a research note on Thursday, September 25th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of uniQure in a research report on Wednesday. Benchmark reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. Royal Bank Of Canada dropped their price target on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a research note on Monday, November 3rd. Finally, The Goldman Sachs Group reduced their price objective on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $60.82.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.